Quarterly report pursuant to Section 13 or 15(d)

Condensed Statements of Operations and Comprehensive Loss (Unaudited)

v3.24.1.1.u2
Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:    
Research and development $ 21,954 $ 12,435
General and administrative 6,077 4,521
Total operating expenses 28,031 16,956
Loss from operations (28,031) (16,956)
Other income:    
Interest income 2,984 1,102
Net loss (25,047) (15,854)
Other comprehensive income:    
Net unrealized (loss) gain on available-for-sale investments, net of tax (77) 47
Net comprehensive loss $ (25,124) $ (15,807)
Net loss per share of voting and non-voting common stock, basic $ (0.51) $ (0.45)
Net loss per share of voting and non-voting common stock, diluted $ (0.51) $ (0.45)